Cargando…

Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

BACKGROUND: The US National Cancer Institute (NCI) has developed the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) to capture patients’ self-reported symptomatic adverse events in cancer clinical trials. The aim of this study was to develop and l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyaji, Tempei, Iioka, Yukiko, Kuroda, Yujiro, Yamamoto, Daigo, Iwase, Satoru, Goto, Yasushi, Tsuboi, Masahiro, Odagiri, Hiroki, Tsubota, Yu, Kawaguchi, Takashi, Sakata, Naoko, Basch, Ethan, Yamaguchi, Takuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934908/ https://www.ncbi.nlm.nih.gov/pubmed/29757296 http://dx.doi.org/10.1186/s41687-017-0012-7

Ejemplares similares

The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events
por: Kawaguchi, Takashi, et al.
Publicado: (2018)

Dutch translation and linguistic validation of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)
por: Veldhuijzen, Evalien, et al.
Publicado: (2020)

The clinical use of Kampo medicines (traditional Japanese herbal treatments) for controlling cancer patients’ symptoms in Japan: a national cross-sectional survey
por: Iwase, Satoru, et al.
Publicado: (2012)

Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
por: Mazza, Gina L., et al.
Publicado: (2021)

Linguistic validation of the simplified Chinese version of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™)
por: KKF, Cheng, et al.
Publicado: (2020)

Correction to: Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2
por: Mazza, Gina L., et al.
Publicado: (2021)

Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients
por: Baeksted, Christina, et al.
Publicado: (2017)

Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)
por: Caminiti, Caterina, et al.
Publicado: (2022)

Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study
por: Matsuoka, Hiromichi, et al.
Publicado: (2017)

Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Schroeder, Kristin M., et al.
Publicado: (2023)

Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
por: Bennett, Antonia V., et al.
Publicado: (2016)

Tackling the Pharmaceutical Frontier: Regulation of Cannabinoid-Based Medicines in Postwar Japan
por: Miyaji, Tempei, et al.
Publicado: (2016)

Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
por: Wang, Tian Qi, et al.
Publicado: (2018)

Veterinary Cooperative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG‐CTCAE v2) following investigational therapy in dogs and cats
por: LeBlanc, Amy K., et al.
Publicado: (2021)

Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period
por: Lee, M. K., et al.
Publicado: (2023)

Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial
por: Yamamoto, Daigo, et al.
Publicado: (2012)

Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report
por: Kawaguchi, Takashi, et al.
Publicado: (2009)

Assessment of Cancer-Related Fatigue, Pain, and Quality of Life in Cancer Patients at Palliative Care Team Referral: A Multicenter Observational Study (JORTC PAL-09)
por: Iwase, Satoru, et al.
Publicado: (2015)

Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE(®) to Provide Two Distinct and Complementary Perspectives
por: Minasian, Lori M, et al.
Publicado: (2022)

Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema
por: Shiraya, Tomoyasu, et al.
Publicado: (2017)

Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02)
por: Ohnishi, Shunsuke, et al.
Publicado: (2017)

The use of and adherence to CTCAE v3.0 in cancer clinical trial publications
por: Zhang, Sheng, et al.
Publicado: (2016)

A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies
por: Regnault, Antoine, et al.
Publicado: (2023)

Protocol for the ASTRO study (SSOP-01): a multicentre prospective cohort study investigating adverse events based on electronic patient-reported outcomes in patients with breast cancer after adjuvant chemotherapy
por: Kuniyoshi, Ouki, et al.
Publicado: (2023)

Integrated communication support program for oncologists, caregivers and patients with rapidly progressing advanced cancer to promote patient-centered communication: J-SUPPORT 1904 study protocol for a randomised controlled trial
por: Fujimori, Maiko, et al.
Publicado: (2020)

Nurse-led, screening-triggered, early specialised palliative care intervention programme for patients with advanced lung cancer: study protocol for a multicentre randomised controlled trial
por: Fujisawa, Daisuke, et al.
Publicado: (2020)

Development of a keyword library for capturing PRO-CTCAE-focused “symptom talk” in oncology conversations
por: Durieux, Brigitte N, et al.
Publicado: (2023)

Adherence to anti-retroviral therapy, decisional conflicts, and health-related quality of life among treatment-naïve individuals living with HIV: a DEARS-J observational study
por: Sekine, Yusuke, et al.
Publicado: (2023)

Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Lee, Minji K., et al.
Publicado: (2020)

Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer
por: Kowalchuk, Roman O., et al.
Publicado: (2021)

Protocol for a multicentre, prospective, cohort study to investigate patient satisfaction and quality of life after immediate breast reconstruction in Japan: the SAQLA study
por: Saiga, Miho, et al.
Publicado: (2021)

Linguistic Validation of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean
por: Cho, Juhee, et al.
Publicado: (2019)

Hydrocolloid dressing as a prophylactic use for hand–foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study
por: Zenda, Sadamoto, et al.
Publicado: (2020)

Registry study of immune-related adverse events using electronic patient-reported outcome in patients with cancer receiving immune checkpoint inhibitors: protocol for a multicentre cohort study
por: Hirata, Taiki, et al.
Publicado: (2023)

Correction to: Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Lee, Minji K., et al.
Publicado: (2021)

Correction to: Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
por: Lee, Minji K., et al.
Publicado: (2023)

THU513 Are Endocrinologists Using CTCAE Grading System For Endocrine Side Effects Of Cancer Treatment With Immune Checkpoint Inhibitors?
por: Arnouk, Nelly, et al.
Publicado: (2023)

Development of Japanese Versions of the Control Preferences Scale and Information Needs Questionnaire: Role of Decision-Making and Information Needs for Japanese Breast Cancer Patients
por: Azuma, Kanako, et al.
Publicado: (2021)

Physics terminology
por: BarCharts
Publicado: (2013)

Building terminology
Publicado: (1974)

Cannot write session to /tmp/vufind_sessions/sess_snn841rk9spde3mnemnitgjmsd